Lignées de carcinome prostatique et apoptose: état de la question

[en] Prostate cancer is a major pathology in industrialized countries. Tumor growth usually results from increased cell proliferation, conjugated with an inhibition of programmed cell death (apoptosis). In this paper, after a short description of the apoptotic mechanisms and their methods of investigation, we review the present knowledge of the implication of different molecular actors in the regulation of apoptosis in prostate cancer cells. This review notably summarizes the present knowledge of the (de)regulation of the effects of androgens, p53, Bcl-2, Bcl-xL, Bax, Akt, PTEN, Par-4, clusterine, caspases and NF-kappaB in prostate adenocarcinoma cell lines and provides an appraisal of their therapeutic potential. A better knowledge of the apoptotic pathways in these cells could indeed allow the development of new selective and effective anti-cancer strategies.

Disciplines :

Urology & nephrology

Author, co-author :

Califice, Stéphane ; Université de Liège - ULiège > Interface Entreprises-Université

Waltregny, David ; Université de Liège - ULiège > Département des sciences cliniques > Urologie - GIGA-R : Labo de recherche sur les métastases

Castronovo, Vincenzo ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Biologie générale et cellulaire - GIGA-R : Labo de recherche sur les métastases

van den Brule, Frédéric

Language :

French

Title :

Lignées de carcinome prostatique et apoptose: état de la question

Alternative titles :

[en] Prostate carcinoma cell lines and apoptosis: A review

Publication date :

December 2004

Journal title :

Revue Médicale de Liège

ISSN :

0370-629X

eISSN :

2566-1566

Publisher :

Université de Liège. Revue Médicale de Liège, Liège, Belgium

Volume :

Issue :

Pages :

704-10

Peer reviewed :

Peer reviewed

Available on ORBi :

since 25 January 2009

Statistics

Number of views

97 (7 by ULiège)

Number of downloads

2 (2 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

Bibliography

Greenlee RT, Murray T, Bolden S et al.- Cancer statistics, 2000. CA Cancer J Clin, 2000, 50 (1), p. 7-33.
Gurumurthy S, Vasudevan KM, Rangnekar VM. - Regulation of apoptosis in prostate cancer. Cancer Metastasis Rev, 2001, 20 (3-4), p. 225-43.
Rokhlin OW, Bishop GA, Hostager BS et al.- Fas-mediated apoptosis in human prostatic carcinoma cell lines. Cancer Res, 1997, 57 (9), p. 1758-68.
Zornig M, Hueber A, Baum W et al.- Apoptosis regulators and their role in tumorigenesis. Biochim Biophys Acta, 2001, 1551 (2), p. F1-37.
Horoszewicz JS, Leong SS, Chu TM et al.- The LNCaP cell line - a new model for studies on human prostatic carcinoma. Prog Clin Biol Res, 1980, 37, p. 115-32.
Horoszewicz JS, Leong SS, Kawinski E et al.- LNCaP model of human prostatic carcinoma. Cancer Res, 1983, 43 (4), p. 1809-18.
Mickey DD, Stone KR, Wunderli H et al.- Characterization of a human prostate adenocarcinoma cell line (DU 145) as a monolayer culture and as a solid tumor in athymic mice. Prog Clin Biol Res, 1980, 37, p. 67-84.
Kaighn ME, Narayan KS, Ohnuki Y et al.- Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol, 1979, 17 (1), p. 16-23.
Iizumi T, Yazaki T, Kanoh S et al.- Establishment of a new prostatic carcinoma cell line (TSU-Pr1). J Urol, 1987, 137 (6), p. 1304-6.
Narayan P, Dahiya R.- Establishment and characterization of a human primary prostatic adenocarcinoma cell line (ND-1). J Urol, 1992, 148 (5), p. 1600-4.
Loop SM, Rozanski TA, Ostenson RC.- Human primary prostate tumor cell line, ALVA-31: a new model for studying the hormonal regulation of prostate tumor cell growth. Prostate, 1993, 22 (2), p. 93-108.
Muraki J, Addonizio JC, Choudhury MS et al.- Establishment of new human prostatic cancer cell line (JCA-1). Urology, 1990, 36 (1), p. 79-84.
Smith M, Kantoff P.- Molecular Biology of Prostate Cancer, in The Molecular Basis of CANCER, 2nd Edition, Mendelson et al, Editors. 2001. p. 343-360.
Tang DG, Porter AT.- Target to apoptosis: a hopeful weapon for prostate cancer. Prostate, 1997, 32 (4), p. 284-93.
Webber MM, Bello D, Quader S.- Immortalized and tumorigenic adult human prostatic epithelial cell lines: characteristics and applications Part 2. Tumorigenic cell lines. Prostate, 1997, 30 (1), p. 58-64.
Kajiwara T, Takeuchi T, Ueki T et al.- Effect of Bcl-2 overexpression in human prostate cancer cells in vitro and in vivo. Int J Urol, 1999, 6 (10), p. 520-5.
Shen Y, White E.- p53-dependent apoptosis pathways. Adv Cancer Res, 2001, 82, p. 55-84.
Finlay CA, Hinds PW, Tan TH et al.- Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol Cell Biol, 1988, 8 (2), p. 531-9.
Webber MM, Bello D, Quader S.- Immortalized and tumorigenic adult human prostatic epithelial cell lines: characteristics and applications. Part 3. Oncogenes, suppressor genes, and applications. Prostate, 1997, 30 (2), p. 136-42.
Carroll AG, Voeller HJ, Sugars L et al.- p53 oncogene mutations in three human prostate cancer cell lines. Prostate, 1993, 23 (2), p. 123-34.
Isaacs WB, Carter BS, Ewing CM.- Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles. Cancer Res, 1991, 51 (17), p. 4716-20.
Burchardt M, Burchardt T, Shabsigh A et al.- Reduction of wild type p53 function confers a hormone resistant phenotype on LNCaP prostate cancer cells. Prostate, 2001, 48(4), p. 225-30.
Nesslinger NJ, Shi XB, deVere White RW.- Androgen-independent growth of LNCaP prostate cancer cells is mediated by gain-of-function mutant p53. Cancer Res, 2003, 63 (9), p. 2228-33.
Schumacher G, Bruckheimer EM, Beham AW et al. - Molecular determinants of cell death induction following adenovirus-mediated gene transfer of wild-type p53 in prostate cancer cells. Int J Cancer, 2001, 91 (2), p. 159-66.
Yin DX, Schimke RT.- BCL-2 expression delays drug-induced apoptosis but does not increase clonogenic survival after drug treatment in HeLa cells. Cancer Res, 1995, 55 (21), p. 4922-8.
Shi XB, Gumerlock PH, Muenzer JT et al.- BCL2 antisense transcripts decrease intracellular Bcl2 expression and sensitize LNCaP prostate cancer cells to apoptosis-inducing agents. Cancer Biother Radiopharm, 2001, 16 (5), p. 421-9.
Raffo AJ, Perlman H, Chen MW et al.- Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res, 1995, 55 (19), p. 4438-45.
Chen X, Thakkar H, Tyan F et al.- Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer. Oncogene, 2001, 20 (42), p. 6073-83.
Nesterov A, Lu X, Johnson M et al.- Elevated AKT activity protects the prostate cancer cell line LNCaP from TRAIL-induced apoptosis. J Biol Chem, 2001, 276 (14), p. 10767-74.
Yuan XJ, Whang YE.- PTEN sensitizes prostate cancer cells to death receptor-mediated and drug-induced apoptosis through a FADD-dependent pathway. Oncogene, 2002, 21 (2), p. 319-27.
Marcelli M, Cunningham GR, Walkup M et al.- Signaling pathway activated during apoptosis of the prostate cancer cell line LNCaP: overexpression of caspase-7 as a new gene therapy strategy for prostate cancer. Cancer Res, 1999, 59 (2), p. 382-90.
Panvichian R, Orth K, Pilat MJ et al.- Signaling network of paclitaxel-induced apoptosis in the LNCaP prostate cancer cell line. Urology, 1999, 54 (4), p. 746-52.
Lebedeva I, Rando R, Ojwang J et al.- Bcl-xL in prostate cancer cells: effects of overexpression and down-regulation on chemosensitivity. Cancer Res, 2000, 60 (21), p. 6052-60.
Marcelli M, Marani M, Li X et al.- Heterogeneous apoptotic responses of prostate cancer cell lines identify an association between sensitivity to staurospoline-induced apoptosis, expression of Bcl-2 family members, and caspase activation. Prostate, 2000, 42 (4), p. 260-73.
Chakraborty M, Qiu SG, Vasudevan KM et al.- Par-4 drives trafficking and activation of Fas and Fas1 to induce prostate cancer cell apoptosis and tumor regression. Cancer Res, 2001, 61 (19), p. 7255-63.
Marcelli M et al.- Caspase-7 is activated during lovastatin-induced apoptosis of the prostate cancer cell line LNCaP. Cancer Res, 1998, 58 (1), p. 76-83.